NBSE(Delisted)
NeuBase TherapeuticsยทNASDAQ
--
--(--)
NBSE Profile
Neubase Therapeutics, Inc.
A pre-clinical stage biopharmaceutical company that developing therapies for rare genetic diseases and cancers caused by mutant genes
350 Technology Drive, Pittsburgh, PA 15219
--
NeuBase Therapeutics, Inc. Incorporated in Delaware on August 4, 2009. This is a biotech company that uses a new synthetic drug to accelerate the genetic revolution. Their platform for modular peptide nucleic acid antisense oligonucleotide output "anti-gene" candidate therapies is designed to combine the specificity of target recognition based on gene sequences with modularity that allows the use of various in vivo delivery technologies to achieve broad and selective tissue distribution capabilities. Considering that every human disease may have a genetic component, their differentiated platform technology has the potential to have a broad impact, addressing disease progression for specific indications by increasing, decreasing or altering gene function at the DNA or RNA level.
